For the Inventor, By the Inventor

Enter assignee name

Pasadena, CA, United States of America

Arrowhead Pharmaceuticals, Inc.

USPTO Granted Patents = 95

CIPO Patents = 21

EPO Patents = 19

Trademarks = 4

Forward Citations = 156

Loading Chart...

Loading Chart...

161 inventors (with patents filed for the assignee):

Tao Pei (30 out of 30 patents)

Darren H Wakefield (26 out of 58 patents)

Zhen Li (26 out of 28 patents)

4. David B Rozema (22 out of 82 patents)

5. David L Lewis (19 out of 43 patents)

6. Lauren Almeida (18 out of 20 patents)

7. Rui Zhu (15 out of 16 patents)

8. Anthony Nicholas (14 out of 14 patents)

9. Steven B Kanner (14 out of 40 patents)

10. Stuart Milstein (12 out of 91 patents)

11. Christine I Wooddell (12 out of 14 patents)

12. Jeffrey Carlson (12 out of 17 patents)

13. Jon E Chatterton (12 out of 47 patents)

14. Aaron Almeida (10 out of 10 patents)

15. Andrei V Blokhin (10 out of 25 patents)

Core Competencies:

RNAi Agents

Activin Receptor-Like Kinase 7

Complement Factor B

Apolipoprotein C-III

Mucin 5AC

Alpha-1 Antitrypsin

Integrin Ligands

Hepatitis B Virus

Xanthine Dehydrogenase

Angiopoietin-Like 3

Organic Compositions

Gene Expression Inhibition

95 patents: Sort by Forward Citations

1. 12442002 - RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use (2025-10-14),

2. 12441756 - 5'-cyclo-phosphonate modified nucleotides (2025-10-14),

3. 12378558 - RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use (2025-08-05),

4. 12365899 - RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) (2025-07-22),

5. 12365897 - RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use (2025-07-22),

6. 12221610 - RNAi agents for inhibiting expression of HIF-2 alpha (), compositions thereof, and methods of use (2025-02-11),

7. 12188017 - Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin (2025-01-07),

8. 12173086 - Alpha-v beta-6 integrin ligands and uses thereof (2024-12-24),

9. 12116573 - Targeting ligands for therapeutic compounds (2024-10-15),

10. 12110492 - RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use (2024-10-08),

11. 12091661 - Organic compositions to treat HSF1-related diseases (2024-09-17),

12. 12065458 - Trialkyne linking agents and methods of use (2024-08-20),

13. 12054718 - RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use (2024-08-06),

14. 11920134 - Compositions and methods for inhibiting expression of RRM2 genes (2024-03-05),

15. 11912997 - RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use (2024-02-27),

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of RNA interference (RNAi) therapeutics. They utilize their proprietary Targeted RNAi Molecule (TRiM™) platform to design and develop RNAi-based drugs to treat various diseases. With a strong pipeline of innovative candidates, Arrowhead aims to address unmet medical needs and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

95 Patents

#4 in Pasadena, CA

#903 in California

#3,808 in US

#7,874 in the World

Pasadena, CA, United States of America

Arrowhead Pharmaceuticals, Inc.

Forward Citations = 156

161 inventors:

Tao Pei (30 out of 30 patents)

Darren H Wakefield (26 out of 58 patents)

Zhen Li (26 out of 28 patents)

4. David B Rozema (22 out of 82 patents)

5. David L Lewis (19 out of 43 patents)

Please report any incorrect information to support@idiyas.com

Loading…